Tianhe Stem Cell Biotechnologies Inc.   Report issue

For profit Phase 2
Founded: Jinan China (2011)

Organization Overview

First Clinical Trial
2019
NCT04011748
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Tianhe Stem Cell Biotechnologies Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alopecia (Phase 2)

Alopecia Areata (Phase 2)

Coronavirus Infections (Phase 2)

Inflammation (Phase 2)

Pneumonia (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3